Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05229042Phase 1Completed

A Study to Investigate the Safety and Efficacy of Ricolinostat

Role: lead

NCT05193851Phase 1Completed

Evaluate the Safety and Pharmacokinetics of Ricolinostat

Role: lead

NCT05133947Completed

Pre-study to Evaluate IENFD Induction in Patients With Taxane-induced CIPN

Role: lead

All 3 trials loaded